Literature DB >> 32479649

First- and third-generation epidermal growth factor receptor inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatological reactions.

C Vasavda1, B K Ho1, D Y Zhang1, K A Williams1, B H Kaffenberger2, S G Kwatra1, M M Kwatra3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32479649      PMCID： PMC7704571          DOI： 10.1111/bjd.19263

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

1.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Authors:  M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

2.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

Review 3.  Mechanisms of cutaneous toxicities to EGFR inhibitors.

Authors:  Mario E Lacouture
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 4.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 5.  Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Authors:  Chia-Yu Chu; Jennifer Choi; Beth Eaby-Sandy; Corey J Langer; Mario E Lacouture
Journal:  Oncologist       Date:  2018-04-12

6.  Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

Authors:  David Planchard; Kathryn H Brown; Dong-Wan Kim; Sang-We Kim; Yuichiro Ohe; Enriqueta Felip; Philip Leese; Mireille Cantarini; Karthick Vishwanathan; Pasi A Jänne; Malcolm Ranson; Paul A Dickinson
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-22       Impact factor: 3.333

7.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.